<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629771</url>
  </required_header>
  <id_info>
    <org_study_id>STU63944</org_study_id>
    <nct_id>NCT01629771</nct_id>
  </id_info>
  <brief_title>Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India</brief_title>
  <official_title>Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the World Health Organization, lymphatic filariasis, a mosquito-borne parasitic
      disease, is the second leading cause of disability worldwide. Across 81 countries,
      approximately 120 million people are infected with the disease, and of those infected, an
      estimated 40% reside in India alone. The most disfiguring symptoms of lymphatic filariasis,
      elephantiasis and lymphedema, cause long-term suffering in patients who are then often
      embarrassed or even rejected from their communities. Because of the disease's debilitating
      physical and social effects on patients, this study will explore the intersection of
      disability and health-related quality of life (HRQoL) in lymphatic filariasis patients in
      India. Specifically, HRQoL and disability in lymphatic filariasis subjects and age- and
      gender- matched control subjects will be compared. Two HRQoL tools , the general Dermatology
      Life Quality Index (DLQI) and a disease-specific instrument developed by a dermatology group
      in India will be used to gauge HRQol. In addition, the demographic and disease-specific
      factors associated with HRQoL and disability in filarial lymphedema subjects will be
      identified.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Domain Scores</measure>
    <time_frame>Assessed after enrollment</time_frame>
    <description>The DLQI is a 10-item questionnaire measuring skin-specific quality of life through six domains: Symptoms &amp; Feelings, Daily Activities, Leisure, Work &amp; School, Personal Relationships, and Treatment. Symptoms &amp; Feelings, Daily Activities, Leisure, and Personal Relationships are each scored from 0 to 3, where 0 is associated with no effect on a patient's life, and 3 is associated with a large effect on a patient's life. Work &amp; School and Treatment are each scored from 0 to 3, where 0 is associated with no effect on a patient's life, and 6 is associated with a large effect on a patient's life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphatic Filariasis-Specific Quality of Life (LFSQQ) Domain Scores</measure>
    <time_frame>Assessed after enrollment</time_frame>
    <description>The LFSQQ was developed to assess quality of life in subjects with lymphatic filariasis through seven domains: Mobility, Self-Care, Usual Activities, Disease Burden, Pain/Discomfort, Psychological Health, and Social Participation. Items are scored on a 5-point scale (no problem, mild, moderate, severe, most severe), and scores for each domain are calculated based on the number of questions answered and the raw scores. Scores for each domain range from 0 to 100, where 0 is associated with a worse quality of life and 100 is associated with a better quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) Domain Scores</measure>
    <time_frame>Assessed after enrollment</time_frame>
    <description>The WHODAS 2.0 is a generic health and disability assessment tool that describes effects of disease on six domains: Cognition, Mobility, Self-Care, Getting Along, Life Activities, and Participation in Society. Responses are measured on a 5-point scale from 1 (no difficulty) to 5 (extreme difficulty or cannot do). Scores are calculated using a WHO SPSS 36 version syntax for employed subjects and a WHO SPSS 32 version syntax for unemployed subjects. Scores for each domain range from 0 to 100, where 0 is associated with no impairment of health status, and 100 is associated with a greater impairment of health status.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">72</enrollment>
  <condition>Lymphatic Filariasis</condition>
  <arm_group>
    <arm_group_label>Lymphatic Filariasis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without Lymphatic Filariasis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be conducted in the Kasaragod district of Kerala, India. Subjects with a
        clinical diagnosis of lymphatic filariasis of a single body part or more will be recruited
        from the Institute of Applied Dermatology, and age-matched controls
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Case Inclusion Criteria

          -  Subjects with a clinical diagnosis of lymphatic filariasis

          -  Subjects over the age of 18 and able to give consent

        Case Exclusion Criteria

          -  Subjects on active treatment for lymphatic filariasis

          -  Subjects who are under the age of 18 or unable to give informed consent

        Control Inclusion Criteria

          -  Subjects without a clinical diagnosis of lymphatic filariasis

          -  Subjects over the age of 18 and able to give consent

        Control Exclusion Criteria

          -  Subjects without a clinical diagnosis of lymphatic filariasis

          -  Subjects who are under the age of 18 or unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roopal Kundu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Applied Dermatology</name>
      <address>
        <city>Kasaragod district</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.feinberg.northwestern.edu/depts/dermatology/research/clinical-trials/ctu-active%20trials.htm</url>
    <description>Northwestern University Department of Dermatology Actively Enrolling Research Trials</description>
  </link>
  <reference>
    <citation>Michael E, Bundy DA, Grenfell BT. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology. 1996 Apr;112 ( Pt 4):409-28. Review.</citation>
    <PMID>8935952</PMID>
  </reference>
  <reference>
    <citation>Coreil J, Mayard G, Louis-Charles J, Addiss D. Filarial elephantiasis among Haitian women: social context and behavioural factors in treatment. Trop Med Int Health. 1998 Jun;3(6):467-73.</citation>
    <PMID>9657509</PMID>
  </reference>
  <reference>
    <citation>Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep. 1993 Dec 31;42(RR-16):1-38.</citation>
    <PMID>8145708</PMID>
  </reference>
  <reference>
    <citation>Dreyer G, Nor√µes J, Figueredo-Silva J. New insights into the natural history and pathology of bancroftian filariasis: implications for clinical management and filariasis control programmes. Trans R Soc Trop Med Hyg. 2000 Nov-Dec;94(6):594-6. Review.</citation>
    <PMID>11198637</PMID>
  </reference>
  <reference>
    <citation>Raju K, Jambulingam P, Sabesan S, Vanamail P. Lymphatic filariasis in India: epidemiology and control measures. J Postgrad Med. 2010 Jul-Sep;56(3):232-8. doi: 10.4103/0022-3859.68650. Review.</citation>
    <PMID>20739779</PMID>
  </reference>
  <reference>
    <citation>Narahari SR, Aggithaya MG, Prasanna KS, Bose KS. An integrative treatment for lower limb lymphedema (elephantiasis). J Altern Complement Med. 2010 Feb;16(2):145-9. doi: 10.1089/acm.2008.0546.</citation>
    <PMID>20180687</PMID>
  </reference>
  <reference>
    <citation>Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6.</citation>
    <PMID>8033378</PMID>
  </reference>
  <reference>
    <citation>International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2009 Concensus Document of the International Society of Lymphology. Lymphology. 2009 Jun;42(2):51-60.</citation>
    <PMID>19725269</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <results_first_submitted>June 3, 2013</results_first_submitted>
  <results_first_submitted_qc>June 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2013</results_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Roopal Kundu</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
    <mesh_term>Elephantiasis</mesh_term>
    <mesh_term>Elephantiasis, Filarial</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects With Lymphatic Filariasis</title>
          <description>Subjects with lymphatic filariasis completed health-related quality of life questionnaires.</description>
        </group>
        <group group_id="P2">
          <title>Control Subjects</title>
          <description>Age- and gender-matched control subjects completed health-related quality of life questionnaires.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Lymphatic Filariasis</title>
          <description>Subjects with lymphatic filariasis completed health-related quality of life questionnaires.</description>
        </group>
        <group group_id="B2">
          <title>Control Subjects</title>
          <description>Age- and gender-matched control subjects completed health-related quality of life questionnaires.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="16.2"/>
                    <measurement group_id="B2" value="52.3" spread="16.1"/>
                    <measurement group_id="B3" value="52.0" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dermatology Life Quality Index (DLQI) Domain Scores</title>
        <description>The DLQI is a 10-item questionnaire measuring skin-specific quality of life through six domains: Symptoms &amp; Feelings, Daily Activities, Leisure, Work &amp; School, Personal Relationships, and Treatment. Symptoms &amp; Feelings, Daily Activities, Leisure, and Personal Relationships are each scored from 0 to 3, where 0 is associated with no effect on a patient's life, and 3 is associated with a large effect on a patient's life. Work &amp; School and Treatment are each scored from 0 to 3, where 0 is associated with no effect on a patient's life, and 6 is associated with a large effect on a patient's life.</description>
        <time_frame>Assessed after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Lymphatic Filariasis</title>
            <description>Subjects with lymphatic filariasis completed health-related quality of life questionnaires.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age- and gender-matched control subjects completed health-related quality of life questionnaires.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI) Domain Scores</title>
          <description>The DLQI is a 10-item questionnaire measuring skin-specific quality of life through six domains: Symptoms &amp; Feelings, Daily Activities, Leisure, Work &amp; School, Personal Relationships, and Treatment. Symptoms &amp; Feelings, Daily Activities, Leisure, and Personal Relationships are each scored from 0 to 3, where 0 is associated with no effect on a patient's life, and 3 is associated with a large effect on a patient's life. Work &amp; School and Treatment are each scored from 0 to 3, where 0 is associated with no effect on a patient's life, and 6 is associated with a large effect on a patient's life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptoms &amp; Feelings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leisure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work &amp; School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal Relationships</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lymphatic Filariasis-Specific Quality of Life (LFSQQ) Domain Scores</title>
        <description>The LFSQQ was developed to assess quality of life in subjects with lymphatic filariasis through seven domains: Mobility, Self-Care, Usual Activities, Disease Burden, Pain/Discomfort, Psychological Health, and Social Participation. Items are scored on a 5-point scale (no problem, mild, moderate, severe, most severe), and scores for each domain are calculated based on the number of questions answered and the raw scores. Scores for each domain range from 0 to 100, where 0 is associated with a worse quality of life and 100 is associated with a better quality of life.</description>
        <time_frame>Assessed after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Lymphatic Filariasis</title>
            <description>Subjects with lymphatic filariasis completed health-related quality of life questionnaires.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age- and gender-matched control subjects completed health-related quality of life questionnaires.</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphatic Filariasis-Specific Quality of Life (LFSQQ) Domain Scores</title>
          <description>The LFSQQ was developed to assess quality of life in subjects with lymphatic filariasis through seven domains: Mobility, Self-Care, Usual Activities, Disease Burden, Pain/Discomfort, Psychological Health, and Social Participation. Items are scored on a 5-point scale (no problem, mild, moderate, severe, most severe), and scores for each domain are calculated based on the number of questions answered and the raw scores. Scores for each domain range from 0 to 100, where 0 is associated with a worse quality of life and 100 is associated with a better quality of life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="58" upper_limit="80"/>
                    <measurement group_id="O2" value="100" lower_limit="88" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-Care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Burden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="60" upper_limit="75"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="83" upper_limit="96"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="64" upper_limit="86"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Participation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="50" upper_limit="85"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) Domain Scores</title>
        <description>The WHODAS 2.0 is a generic health and disability assessment tool that describes effects of disease on six domains: Cognition, Mobility, Self-Care, Getting Along, Life Activities, and Participation in Society. Responses are measured on a 5-point scale from 1 (no difficulty) to 5 (extreme difficulty or cannot do). Scores are calculated using a WHO SPSS 36 version syntax for employed subjects and a WHO SPSS 32 version syntax for unemployed subjects. Scores for each domain range from 0 to 100, where 0 is associated with no impairment of health status, and 100 is associated with a greater impairment of health status.</description>
        <time_frame>Assessed after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Lymphatic Filariasis</title>
            <description>Subjects with lymphatic filariasis completed health-related quality of life questionnaires.</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects</title>
            <description>Age- and gender-matched control subjects completed health-related quality of life questionnaires.</description>
          </group>
        </group_list>
        <measure>
          <title>World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) Domain Scores</title>
          <description>The WHODAS 2.0 is a generic health and disability assessment tool that describes effects of disease on six domains: Cognition, Mobility, Self-Care, Getting Along, Life Activities, and Participation in Society. Responses are measured on a 5-point scale from 1 (no difficulty) to 5 (extreme difficulty or cannot do). Scores are calculated using a WHO SPSS 36 version syntax for employed subjects and a WHO SPSS 32 version syntax for unemployed subjects. Scores for each domain range from 0 to 100, where 0 is associated with no impairment of health status, and 100 is associated with a greater impairment of health status.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cognition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="3" upper_limit="20"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="19" upper_limit="69"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-Care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Getting Along</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="0" upper_limit="33"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="0" upper_limit="40"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participation in Society</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="17" upper_limit="38"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects With Lymphatic Filariasis</title>
          <description>Subjects with lymphatic filariasis completed health-related quality of life questionnaires.</description>
        </group>
        <group group_id="E2">
          <title>Control Subjects</title>
          <description>Age- and gender-matched control subjects completed health-related quality of life questionnaires.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Unit Coordinator</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-6829</phone>
      <email>j-bae@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

